Comparison of effects of azelnidipine and trichlormethiazide in combination with olmesartan on blood pressure and metabolic parameters in hypertensive type2 diabetic patients

Journal of Diabetes Investigation

Volumn 2, Issue 6, 2011, Pages 490-496

  Yoshii, Hidenori ^a   Mita, Tomoya ^a   Sato, Junko ^a   Kodama, Yuuki ^a   Choi, Jong Bock ^b   Komiya, Koji ^a   Matsumoto, Kazuhisa ^c   Kanno, Rei ^a   Kawasumi, Masahiko ^c   Koyano, Hajime ^a   Hirose, Takahisa ^a   Onuma, Tomio ^a   Kawamori, Ryuzo ^d   Watada, Hirotaka ^a,d  

^a JUNTENDO UNIVERSITY URAYASU HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^c JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

^d JUNTENDO UNIVERSITY   (Japan)

Author keywords

AngiotensinII type1 receptor blockers; Calcium channel blocker; Thiazide diuretic

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; AZELNIDIPINE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; OLMESARTAN; THIAZIDE DIURETIC AGENT; TRICHLORMETHIAZIDE; URIC ACID;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC HYPERTENSION; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; JAPANESE; LOW DRUG DOSE; MALE; METABOLIC PARAMETERS; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE RATE; SYSTOLIC BLOOD PRESSURE; URIC ACID BLOOD LEVEL;

EID: 84859815096     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00135.x     Document Type: Article

References (41)

1. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319-325.
2. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
3. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713.
4. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
5. Japanese Society of Hypertension. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res 2006; 29(Suppl.): S1-S105.
6. Dzau VJ. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052.
7. Zhang C, Hein TW, Wang W, et al. Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res 2003; 92: 322-329.
8. Nakayama S, Watada H, Mita T, et al. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension. Hypertens Res 2008; 31: 7-13.
9. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5: 41-50.
10. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3: 283-291.
11. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
12. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277: 739-745.
13. London GM, Asmar RG, O'Rourke MF, et al. Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004; 43: 92-99.
14. Reungjui S, Pratipanawatr T, Johnson RJ, et al. Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia. Curr Opin Nephrol Hypertens 2008; 17: 470-476.
15. Reungjui S, Roncal CA, Mu W, et al. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J Am Soc Nephrol 2007; 18: 2724-2731.
16. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-2225.
17. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
18. Dahlof B. Management of cardiovascular risk with RAS inhibitor/CCB combination therapy. J Hum Hypertens 2009; 23: 77-85.
19. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.
20. Seino Y, Nanjo K, Tajima N, et al. Report of the Committee On the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
21. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
22. Reyes AJ. Diuretics in the therapy of hypertension. J Hum Hypertens 2002; 16(Suppl. 1): S78-S83.
23. Matsui Y, Eguchi K, O'Rourke MF, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009; 54: 716-723.
24. Ishimitsu T, Numabe A, Masuda T, et al. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res 2009; 32: 962-968.
25. Kuramoto K, Ichikawa S, Hirai A, et al. Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. Hypertens Res 2003; 26: 201-208.
26. Nakamura T, Sugaya T, Kawagoe Y, et al. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci 2007; 333: 321-326.
27. Nada T, Nomura M, Koshiba K, et al. Clinical study with azelnidipine in patients with essential hypertension. Antiarteriosclerotic and cardiac hypertrophy-inhibitory effects and influence on autonomic nervous activity. Arzneimittelforschung 2007; 57: 698-704.
28. Gillman MW, Kannel WB, Belanger A, et al. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993; 125: 1148-1154.
29. Hozawa A, Ohkubo T, Kikuya M, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens 2004; 17: 1005-1010.
30. Seccareccia F, Pannozzo F, Dima F, et al. Heart rate as a predictor of mortality: the MATISS project. Am J Public Health 2001; 91: 1258-1263.
31. Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149-1154.
32. Alderman MH, Cohen H, Madhavan S, et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144-150.
33. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963-969.
34. Andersson OK, Gudbrandsson T, Jamerson K. Metabolic adverse effects of thiazide diuretics: the importance of normokalaemia. J Intern Med Suppl 1991; 735: 89-96.
35. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002; 282: F991-F997.
36. Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004; 44: 642-650.
37. Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-59.
38. Fujimoto S, Satoh M, Nagasu H, et al. Azelnidipine exerts renoprotective effects by improvement of renal microcirculation in angiotensin II infusion rats. Nephrol Dial Transplant 2009; 24: 3651-3658.
39. Bakris GL, Toto RD, McCullough PA, et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008; 73: 1303-1309.
40. Ohmura C, Watada H, Shimizu T, et al. Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure. Endocr J 2007; 54: 805-811.
41. Sato A, Watanabe S, Okubo S, et al. The therapeutic importance of home blood pressure assessment and combination antihypertensive therapy for achieving target blood pressure control: Ibaraki hypertension assessment trial. Hypertens Res 2010; 33: 1264-1271.